Haleon Pakistan Limited (PSX:HALEON)

Market Cap	80.67B -16.3%
Revenue (ttm)	43.11B +15.9%
Net Income	6.37B +39.2%
EPS	54.45 +39.2%
Shares Out	117.05M
PE Ratio	12.66
Forward PE	10.77
Dividend	30.00 (4.35%)
Ex-Dividend Date	Apr 21, 2026

Volume	24,084
Average Volume	67,713
Open	689.90
Previous Close	681.06
Day's Range	680.00 - 697.00
52-Week Range	653.14 - 1,010.00
Beta	0.32
RSI	31.43
Earnings Date	Apr 28, 2026

About Haleon Pakistan

Haleon Pakistan Limited engages in the manufacture, marketing, and sale of consumer healthcare products in Pakistan, rest of Asia, Africa, Australia, North America, the Middle East, and Europe. The company offers oral health, pain relief, wellness and nutrition, and respiratory health products, as well as over-the-counter pharmaceutical products. It sells its products primarily under the Panadol, CaC-1000 Plus, Sensodyne, paradontax, T-Day, ENO, Hydrozole, Qalsium-D, and Voltral Emulgel brands. The company also exports its products to Vietnam, ...

• Industry: Pharmaceutical Preparations
• Founded: 2015
• Employees: 450
• Stock Exchange: Pakistan Stock Exchange
• Ticker Symbol: HALEON

Financial Performance

In 2025, Haleon Pakistan's revenue was 43.11 billion, an increase of 15.86% compared to the previous year's 37.21 billion. Earnings were 6.37 billion, an increase of 39.21%.